A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

This study has been completed.

Study NCT00000972 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

First Received: November 2, 1999 Last Updated: June 23, 2005 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given